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Introduction
The current reference standard for the diagnosis of osteoporosis 
and assessment of fracture risk is measurement of bone mine ral 
density (BMD) using dual-energy X-ray absorptiometry (DXA). 
In the developed world, the lifetime risk of a fracture in Cauca-
sian women is between 30% and 40%.1 Femoral neck fracture has 
the highest mortality rate of any type of fragility fracture,2 with 
incidence increasing exponentially with age.3,4 Responding to the 
rising population burden of the disease, the World Health Orga-
nization (WHO) has identified a need for improved prognostic 
indicators and alternatives to BMD-based diagnostic tools to 
assess fracture risk.1,5 Recently, there has been a trend toward the 
use of BMD measurements in combination with other clinical 
risk factors in order to improve overall predictive performance.6,7 
A clinically accepted risk calculator is the QFracture tool for 
assessment of fracture risk.8 Clinical variables evaluated in the 
QFracture algorithm in men and women are age, sex, body mass 
index (BMI), smoking, alcohol intake, glucocorticoid use, asthma, 
cardiovascular disease, history of falls, chronic liver disease, rheu-
matoid arthritis, type 2 diabetes, and tricyclic antidepressants. 
Additional factors used in women only are hormone replacement 
therapy, parental history of hip fracture, menopausal symptoms, 
gastrointestinal malabsorption, and other endocrine disorders.9 
Screening programmes that use a simple initial assessment such 
as QFracture may be able to target further evaluation in subjects 
identified as being at very high risk of fracture.
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AbstrAct: Raman spectroscopy was applied to nail clippings from 633 postmenopausal British and Irish women, from six clinical sites, of whom 42% 
had experienced a fragility fracture. The objective was to build a prediction algorithm for fracture using data from four sites (known as the calibration set) 
and test its performance using data from the other two sites (known as the validation set). Results from the validation set showed that a novel algorithm, 
combining spectroscopy data with clinical data, provided area under the curve (AUC) of 74% compared to an AUC of 60% from a reduced QFracture score 
(a clinically accepted risk calculator) and 61% from the dual-energy X-ray absorptiometry T-score, which is in current use for the diagnosis of osteoporosis. 
Raman spectroscopy should be investigated further as a noninvasive tool for the early detection of enhanced risk of fragility fracture.
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Anecdotally, patients diagnosed with osteoporosis have 
reported loss of fingernail resilience10 with disease progression. 
Attempts have been made to investigate potential associa-
tions between aspects of nail composition and osteoporosis or 
fracture risk. Bahreini et al.11 demonstrated some correlation 
between individual fingernail elements and BMD using 
laser-induced breakdown spectroscopy; however, there was 
no correlation between fingernail elements and osteoporosis 
or fracture risk. Vecht-Hart et al tested cation concentrations 
in fingernail sourced from subjects and found no significant 
correlation between calcium or magnesium concentrations 
and BMD.12 However, a study completed 10 years later by 
Ohgitani et al concluded that nail mineral content, specifi-
cally calcium and magnesium concentrations, could be used 
as an indicator of BMD.13 The discrepancy between these last 
two studies may reflect the complex nature of bone metabo-
lism and/or the variation between different techniques.
Preliminary studies by the authors have suggested a 
possi ble relationship between human fingernail structure, 
osteoporosis, and fracture risk14–17 using Raman spectros-
copy, an optical analytical technique for obtaining vibra-
tional information on molecules in a sample excited by a 
laser source. The spectrum of a sample with many different 
molecules is a linear combination of the spectra of all the 
Raman active molecules in the sample and can be regarded 
as an optical molecular fingerprint of the sample.18 Kera-
tin and type I collagen are the two key proteins in nail and 
bone, respectively. They both undergo posttranslational and 
nonenzymatic modifications. Raman spectroscopy can iden-
tify such changes,19–21 but the tissue under analysis needs 
to be accessible, and so we have chosen to study the nail. 
We speculate that the degree of posttranslational modifica-
tion of keratin and type I collagen is associated. Collagen 
and keratin are both fibrous proteins that serve structural 
and mechanical roles in the body, providing a strong flexible 
framework for the support of cells and tissues. Both proteins 
consist of polypeptide chains formed by amino acid conden-
sation22 and express the same characteristic bands (CH2 and 
amide I) in the 1200–1800 cm−1 region of Raman spectra.23 
It is valid, then, to speculate that the degree of posttranslational 
modification of keratin and type I collagen are associated. The 
research contained herein is motivated by this hypothetical 
link between bone collagen and nail keratin.
The authors incorporated the Raman data derived from 
the nails of the subjects into an algorithm that provides an 
assessment of underlying bone health as pertaining to the risk 
of a fragility fracture. The primary objective of this study was 
to determine the sensitivity and specificity of the Raman spec-
troscopic method in discriminating between subjects who have 
fractured in the absence of major trauma after the age of 45 years 
and subjects who have never had a fracture in adulthood. The 
secondary objective of the study was to determine whether the 
information provided by the Raman spectra is different to that 
obtained from existing methods of determining bone health 
and whether combining the Raman data with information from 
those existing standards will enhance discrimination.
Materials and Methods
study design and patient population. A clinical study 
entitled Fracture Risk Assessment Nail correlation (FRAN) 
was designed to test the link between the nail keratin and 
the current status of bone health. This was a cross-sectional, 
international, and multicenter study to determine the 
sensitivity and specificity of Raman spectroscopy for assess-
ing fracture risk. A total of 633 eligible women were recruited 
in this study, and two distinct gold standard measurements 
of bone health were recorded for each patient, namely frac-
ture history and BMD, the latter as measured by DXA. The 
research presented here was carried out in compliance with 
the Declaration of Helsinki. Sample collection was carried 
out at six centers across the UK and Ireland, and ethical 
approval was obtained through a multicentre research eth-
ics committee application (MREC number 07/Q1704/1). The 
centers were Southampton University Hospitals NHS Trust 
(Southampton, England, UK), Western General Hospital 
Edinburgh (Edinburgh, Scotland, UK), Sheffield Teaching 
Hospitals NHS Foundation Trust (Sheffield, England, UK), 
Cardiff University Academic Centre Llandough Hospital 
(Cardiff, Wales, UK), Greater Glasgow and Clyde NHS 
Trust (Glasgow, Scotland, UK), and Mid-Western Regional 
Hospital Limerick (Limerick, Ireland), providing a wide geo-
graphical distribution in terms of the British Isles. Patients 
presenting for a DXA scan at each participating center were 
invited to enroll and subjected to a series of inclusion and 
exclusion criteria that are briefly summarized as follows:
Inclusion criteria: active (ambulatory) Caucasian females 
aged between 50 and 85 years (inclusive) who were at least 
5 years postmenopause and had at least 2 mm of clippable nail.
Exclusion criteria:
a. History of metabolic bone diseases such as hyper- or 
hypothyroidism, Paget’s disease of bone or osteomalacia, 
or other potentially confounding diseases such as Celiac 
or Crohn’s disease, chronic liver disease, stage 4 or 5 
chronic kidney disease, hyper- or hypoandrenocortism, 
or any malignant disease in previous 5 years.
b. A current or recent prescription of a bone active medi-
cation such as bisphosphonates (a history of more than 
1 week), strontium ranelate (a history of more than 
1 week), calcitonin (within 3 months), therapeutic 
vitamin D (.1000 IU daily), estrogen (within 6 months) 
or selective estrogen receptor modulators (SERMs, 
within 6 months), fluoride supplements (.2 mg day−1 flu-
oride within the previous 2 years), any as yet unstudied or 
unapproved drugs, aromatase inhibitors, or concomitant 
use of corticosteroids.
c. Any fractures with a traumatic cause (eg, road traffic 
accident).
Raman spectroscopic analysis of fingernail clippings
111CliniCal MediCine insights: arthritis and MusCuloskeletal disorders 2016:9
The patients in the study were divided into the following 
two groups for the purpose of classification and comparison:
1. Nonfracture group: women with no history of fracture.
2. Fracture group: women with a history of fracture (exclud-
ing major trauma, eg, car crash) of the proximal femur 
(hip), vertebra, proximal humerus (upper arm), pelvis, or 
distal radius (wrist), after the age of 45 years.
Fingernail tissue sourcing. Subjects were asked to remove 
any nail polish before presenting and to clean their hands thor-
oughly with warm soapy water. Fingernail samples were clipped, 
using nail scissors, from the largest nail available (.2 mm depth 
of clipping possible) on each hand, and the samples were then 
placed in a 1.5-mL microtube labeled with a unique identifier 
code. This code allowed identification of the collection center 
but not the patient. The samples were stored at room tempera-
ture and shipped to a central laboratory for analysis.
A clinical health questionnaire was also completed by 
each subject and included questions pertinent to bone health 
such as age, previous fractures, number of falls experienced, 
alcohol use (, or $14 units per week), smoking habits (never, 
past, current), medications, menstruation history, relevant 
pathologies, date of birth, height (cm), and weight (kg). The 
height and weight were also used to calculate BMI.
dXA scans. Subjects underwent DXA scans, as per 
WHO guidelines,24 in the relevant UK or Irish health care 
center, and the resulting BMD (in g cm−2) for anteroposte-
rior lumbar vertebrae, total femoral neck, and lowest BMD 
at either right or left femoral neck was recorded. BMD was 
transformed into a DXA T-score according to the specifica-
tions of the manufacturer/model of each scanner used. The 
study did not follow up the subjects nor were they required by 
the study to return to the clinic for further procedures. Aside 
from DXA scans and the collection of nail samples, no addi-
tional procedures were performed.
raman spectroscopy analysis. Raman spectroscopy 
analysis was carried out using a Sierra Reader (Snowy Range 
Instruments) using 785 nm excitation with 50 mW power at 
the sample. Measurements were carried out by three operators 
blind to clinical details, based at one location, and using one 
instrument. Triplicate, spatially separated measurements, each 
lasting 1 minute, were carried out on each sample. The nails 
were inspected to confirm they were free of visible contamina-
tion and then placed so that the upper surface of the nail faced 
the laser exit aperture. No further sample preparation was 
undertaken. Of the 633 samples analyzed, only one (a fracture 
case in the calibration set) did not give a useable Raman signal, 
as the detector saturated. The Raman data collected from the 
nails were processed using singular value decomposition-based 
background removal,25,26 normalized to the first principal 
component (PC) score, using Matlab 2013a.27,28 Spectra were 
acquired from 400 to 1800 cm−1, and this full spectral range 
was used for the data processing and analysis (see below).
calibration and validation. The spectral data acquisition 
and subsequent data processing and statistical analysis have 
been modified from the original protocol proposed for the 
study. In order to provide an independent assessment of the 
analytic method and data analysis model, the data were split 
into two sets, one used for optimizing all aspects of the analy-
sis and the other for validating the full analytical process.
The calibration set was made up of complete data from 
four centers, together providing approximately 75% of the total 
samples for the study. Data from the two remaining sites were 
used for validation. This analysis design ensured that between 
the two phases, DXA scans, questionnaires, and samples 
were collected and processed by different pools of operators, 
and patients were drawn from regions that were geographi-
cally distinct. The aim was to mimic a real-world-independent 
application of the method.
The data processing procedures (preprocessing) for the 
Raman data were created based on the calibration set alone, 
blind to clinical data. Next, for the purposes of analytical algo-
rithm development, the fracture status and clinical data of the 
samples in the calibration set (only) were unblinded. Once the 
signal preprocessing and analytical (risk) algorithms had been 
locked on the basis of the calibration data, Raman scores were 
calculated using parameters derived during the calibration 
phase, for the two centers in the validation set (Edinburgh 
and Cardiff). Finally, the clinical data for the validation set 
were unblinded, and the risk scores calculated from the algo-
rithms were compared to the incidence of fracture, allowing 
an independent evaluation of test performance.
statistical analysis. Analyses were performed in Matlab 
2013a and R version 3.2.2.29 The following key clinical 
parameters, elements of QFracture, were considered: age, 
BMI, alcohol intake, smoking status, number of falls, use 
of anticonvulsants, and parental history of osteoporosis. In 
order to assess differences between fracture and nonfracture 
groups, continuously distributed parameters were first tested 
for approximate normality using the Kolmogorov–Smirnov 
goodness-of-fit test. A Student’s t-test was applied for para-
meters showing approximate normality, and a Wilcoxon rank 
sum test was applied otherwise. Categorical variables were 
tested using a Chi-squared test. The results of these statistical 
comparisons are found in Supplementary Table 1.
Risk prediction scores. For comparison purposes, a number 
of models were considered, models based on the individual 
methods and models based on each permutation of combing 
those methods.
The Raman score was derived as follows. The dimension-
ality of the Raman data was reduced using principal compo-
nents analysis (PCA), calculating the PCA model blind to 
the fracture outcome of the sample. In order to reduce the 
risk of overfitting further, the PC scores for each component 
were compared based on fracture incidence and those with a 
P-value .0.05 for association with fracture were excluded. 
Remaining PC scores (eight were found to be significant) 
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were used to build a classification model using linear 
discriminant analysis.
The minimum T-score arising from DXA scans of lumbar 
spine, total hip, and femoral neck was considered as a continu-
ous measure and shall henceforth be referred to as DXA score.
The clinical score was derived by using the clinical variables 
listed previously and using the published relative weightings 
to calculate a truncated QFracture score.8 It is acknow-
ledged that due to the lack of availability of certain QFracture 
parameters, some test performance will have been lost in the 
current application.
The combined models were created by converting both 
the DXA T-score and the Raman score to a relative risk of 
fracture. The relationship between relative risk of fracture 
and the scores was calculated by means of regression lines 
between scores (average score per 1SD of variation) and risk 
of fracture. This allows the relationship between each score 
type and the relative risk of fracture to be determined in a 
format compatible with the relative risk of fracture used to 
calculate QFracture.
Test performance calculations. The scores were characteri zed 
in the validation data using receiver–operating characteri stic 
(ROC) curves, making use of sensitivity and specificity over 
a range of diagnostic thresholds. For each, the area under the 
curve (AUC) was calculated, and the four scores were ranked 
accordingly. In order to determine whether improvements in 
AUC were statistically significant, pairs of scores were tested 
using the DeLong method,30 in which significant differences 
were found, the net reclassification improvement (NRI) and 
the integrated discrimination improvement (IDI), a general-
ization of NRI, were calculated as well.
Interaction between Raman test and other parameters. The 
degree of interaction between the results of the Raman-
based test and the other parameters used within the study 
was assessed using least squares correlation analysis for all 
parameters with a continuous numeric scale, while the results 
of parameters with ordinal or categorical data were assessed 
using logistic regression. These data are presented in Supple-
mentary Table 1.
results
raman spectra of human fingernails. Figure 1 shows 
the spectra obtained from the fingernails recorded from 
the fracture group (red) and the nonfracture group (green). 
Detailed discussion of the spectral differences is beyond the 
scope of this manuscript, but briefly, the Raman spectra offer 
information on the protein structure in the nail.31,32 The pri-
mary structures of nail protein are the amino acid residues; 
the peak labeled “phe” is related to the content of a particular 
amino acid residue, phenylalanine, which is much stronger in 
the fracture group. The secondary structure of proteins reflects 
how the sequence of amino acid residues organizes themselves 
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Figure 1. Partial subtraction raman spectra of the fracture group (red) and the nonfracture group (green). also included is the one to one subtraction 
(black) and some key peak assignments. Protein secondary structure indicated by α (alpha helical), β (beta sheet), and random, S-S indicates disulfide 
bonds, s-h free sulfydryl bonds, and Phe phenylalanine.
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relative to neighboring residues (whether they adopt helices, 
beta sheets, turns, or nonsystematic random conformations). 
The peaks labeled “α” are peaks that are known to be related 
to alpha helical content, and these show that the nonfracture 
group has a higher alpha helical content. Tertiary protein struc-
ture describes how the secondary structures are then folded 
together, while quaternary protein structure is how individual 
peptides (continuous lengths of amino acid residues) interact 
with each other to form superstructures. The peaks labeled 
“S-S” and “S-H” are related to the degree to which cysteine 
(side group is S-H) bonds to itself (forming cystine, side group 
is S-S), and these are critical in determining the tertiary struc-
ture and the quaternary structure of proteins. The spectral 
differences suggest that there are measureable changes in all 
levels of protein structure within the fingernails of the subjects 
in the fracture group compared with the subjects in the non-
fracture group.
clinical features. As shown in Table 1, the calibration 
and validation sets were well matched in terms of age, height, 
weight, and thus BMI. Although the calibration set was com-
posed of 40% fracture cases, however, the validation set was 
composed of 53% fracture cases. The comparisons of fracture 
versus nonfracture groups showed differences in age (P = 0.02), 
anticoagulant use (P = 0.03), and number of falls (P , 0.001); 
other differences were not statistically significant.
Interaction of individual raman model and risk fac-
tors. None of the continuous factors show a strong correlation 
to the Raman score (Supplementary Table 1), with the highest 
least squares correlation at 0.08 meaning that at most 8% of the 
variation in the Raman score can be explained by a continuous 
clinical parameter recorded within this study. The individual 
correlations for specific DXA sites are R2 = 0.02 and 0.012 for 
the lumbar spine (vertebra) and femoral neck (hip) sites.
None of the binomial parameters showed a significant 
difference in Raman score between the categories. For the 
multinomial parameters, logistic regressions failed to identify 
significant trends for the two of the parameters.
score performance. Table 2 lists the values of parameters, 
as calculated in the validation set (n = 179), used to evaluate 
the comparative effectiveness of classification using different 
inputs. For the individual tests, the AUC is highest for the 
Raman data (67% test, P , 0.05) compared with DXA (57%, 
P , 0.05) and CRFs (61%, P , 0.05). Scores were placed 
in increasing order of AUC, from clinical (AUC = 0.60) to 
Raman/clinical (AUC = 0.74), and a significance test was 
applied to compare each AUC with each model built on 
individual data type.
There were three key findings. First, all the models built 
on individual approaches were statistically significant, with 
the Raman spectra yielding the best numerical result.
Second, the estimates of AUC for clinical score, DXA 
score, and DXA/clinical score were not significantly different 
from one another; all yielded similar test performance.
Third, the combined Raman/clinical score provided a 
clear improvement over and above the DXA/clinical score 
(P = 0.009). The addition of the DXA scores to the combined 
Raman/clinical score did not improve the performance of the 
classifier. Figure 2A shows the ROC curves for the discrimi-
nant score derived from each of the individual models, while 
Figure 2B shows the ROC curves for the scores derived from 
the combined models.
For the purposes of reclassification analysis, the latter two 
scores were rescaled to a common [0–1] range, by subtraction 
of the minimum and division by the range. The comparison of 
Raman/clinical versus DXA/clinical had P = 0.276 for NRI 
and P = 0.037 for IDI.
In order to characterize further the performance of the 
Raman/clinical score in the validation set, the sensitivity and 
specificity arising from different diagnostic thresholds are 
shown in Table 3. It is noted that for the current noninvasive 
method, some reduction in specificity may be tolerated in the 
interests of increased sensitivity. In other words, for postmeno-
pausal subjects who have the opportunity to make dietary and 
table 1. summary of key clinical characteristics of the participants 
in the study. Counts are given with percentages in parentheses; 
continuous variables are given by the mean ± standard error.
vARiABlE SEt NoN-FRACtuRE FRACtuRE
n Calibration 266 (60%) 178 (40%)
Validation 96 (47%) 84 (53%)
age (y) Calibration 66.1 ± 6.4 67.7 ± 7.9
Validation 65.8 ± 7.6 67.6 ± 7.1
height (m) Calibration 1.604 ± 0.060 1.590 ± 0.063
Validation 1.586 ± 0.061 1.594 ± 0.055
Weight (kg) Calibration 70.2 ± 13.3 69.9 ± 13.5
Validation 69.2 ± 11.6 66.4 ± 12.4
BMi (kg/m2) Calibration 27.3 ± 5.1 27.6 ± 5.1
Validation 27.6 ± 4.6 26.1 ± 4.8
table 2. arear under the Curve (auC) in the validation set for the 
four scores. A DeLong confidence interval is provided. The P-value 
indicates the significance of the difference in AUC, in comparison to 
the row above.
SCoRE AuC [95%  
CoNFiDENCE  
iNtERvAl]
P-vAluE (tWo-SiDED)
CliNiCAl DXA RAmAN
Clinical 0.60 [0.51–0.68] – 0.787 0.104
dXa 0.61 [0.53–0.69] 0.787 – 0.180
raman 0.69 [0.61–0.77] 0.104 0.180 –
dXa/ Clinical 0.62 [0.54–0.71] 0.049 0.729 0.250
raman/dXa 0.61 [0.53–0.69] 0.787 1.000 0.180
raman/ Clinical 0.74 [0.66–0.81] 0.001 0.023 0.310
raman/dXa/ 
Clinical
0.74 [0.67–0.81] 0.001 0.002 0.293
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lifestyle changes in order to reduce their risk of fracture, false 
positives may be less damaging than false reassurance. Table 3 
also shows the effect of varying the decision threshold on diag-
nostic accuracy and positive and negative predictive values.
The diagnosis of osteoporosis, according to DXA, correctly 
eliminated 80% of the nonfracture controls within the study from 
being identified as at-high-risk of fracture. This is equivalent to 
specificity if an osteoporosis diagnosis is considered equivalent 
to assigning a person to a high-risk fracture group. In contrast, 
only 25% of the fracture cases within the study were diagnosed 
as osteoporotic ie, 75% of the fracture cases would have been 
placed in the non-intervention, lower risk category if based on 
this test alone. Given that an osteoporotic diagnosis is labeling 
the patient as diseased and considered at high risk of fracture, 
this value of 25% will be considered equivalent to the sensitivity 
to fracture. To compare the sensitivity of the tests on an equal 
footing, the specificity for the other sources of information was 
set to the value closest to 80%. The sensitivity at specificity clos-
est to 80% for Raman spectroscopy alone is 42%, and when the 
Raman score was combined with the reduced QFracture score, 
the sensitivity achieved is 52% (data not shown in Table 3 as 
this table corresponds to fixed intervals of decision threshold).
discussion
The results demonstrate that the Raman spectra of human 
finger nails may be used to discriminate between postmeno-
pausal patients who have sustained a fragility fracture and 
those who have not. Of the individual tests, it gave the best 
AUC, while combining it with clinical variables gave a statisti-
cally significant difference in its AUC compared to all other 
individual model scores, showing that it provides additional 
information beyond earlier established methods. It suggests 
that combining the Raman data with the clinical information 
provides more insight into the underlying bone health of the 
subjects in the study than has hitherto been possible.
The performance of the Raman/clinical algorithm was very 
similar between calibration and validation (AUC = 0.73 in cal-
ibration; AUC = 0.74 in validation), suggesting that the model 
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Figure 2. roC curves for the fracture risk models built on (A) individual approaches and (B) combined approaches.
table 3. test performance of the raman/Clinical score, for different diagnostic thresholds.
DiAgNoStiC tHRESHolD PRoPoRtioN oF FRAN  
vAliDAtioN ‘PoSitivE’
SENSitivitY SPECiFiCitY ACCuRACY PPv NPv
5.70 0.11 0.13 0.91 0.55 0.58 0.54
4.50 0.20 0.30 0.88 0.61 0.69 0.59
4.20 0.31 0.47 0.82 0.65 0.70 0.63
4.00 0.45 0.65 0.72 0.69 0.68 0.70
3.90 0.53 0.76 0.67 0.71 0.67 0.76
3.70 0.68 0.87 0.47 0.66 0.60 0.80
3.60 0.73 0.89 0.40 0.63 0.57 0.80
3.40 0.82 0.95 0.28 0.60 0.54 0.87
3.10 0.91 0.99 0.13 0.53 0.50 0.92
Raman spectroscopic analysis of fingernail clippings
115CliniCal MediCine insights: arthritis and MusCuloskeletal disorders 2016:9
is stable and can be applied to a wider population than was 
captured in the calibration set. The geographical distribution of 
the calibration and validation sets spans all the major regions of 
the British Isles including the Republic of Ireland.
The underlying link between nail keratin composition/
structure and bone health has not been fully elucidated, but 
a number of studies have shown a link between the chemical 
composition of nail and fracture risk/bone health.14–17,33 In our 
published preliminary studies investigating the link between 
collagen and keratin, the mean elastic modulus and hardness 
as measured by nanoindentation were lower in osteoporotic 
patients than in controls, although this did not reach signifi-
cance14; however, disulfide bond (S-S) content of fingernail was 
found to be significantly lower in the osteoporotic group.14,17 A 
further study population16comprised 159 women of whom 81 
were premenopausal and 78 were postmenopausal. A total of 34 
fracture cases were recorded with 16 occurring in the premeno-
pausal and 18 occurring in the postmenopausal women. Sig-
nificantly lower disulfide content of fingernails was observed in 
subjects with a history of fracture. In compari son to the other 
methods used in this study (DXA, biomarkers), the Raman 
test discriminated most accurately between the control and the 
fracture cases (P = 0.003). There is little in the literature to 
directly link S-S and S-H bonding to osseous changes, but the 
presence of these bonds is acknowledged to play a direct role 
on bone formation and subsequent strength: Both collagen and 
keratin require cysteine incorporation and sulfation for struc-
tural integrity; S-S bonding is essential for procollagen fold-
ing and stability of mature collagen,34 and the biosynthesis of 
procollagen requires both intra- and inter-chain disulfide bond 
formation. Noncollagenous proteins in the organic matrix of 
bone such as osteonectin also require disulfide bonding for sta-
bility.35 It has been reported that postmenopausal women with 
osteoporosis have elevated total homocysteine (Hcy) and sig-
nificantly reduced plasma cysteine (Cys) levels in comparison to 
their healthy counterparts.36 The inverse relationship between 
total Hcy and Cys might imply that a trans-sulfuration defect 
could be impairing the irreversible conversion of total Hcy to 
Cys. The authors suggest that a low Cys concentration, possibly 
due to reduced flux from Hcy, may lead to less availability for 
collagen formation, resulting in poor bone quality.36
The mineral phase of bone provides strength (the ability to 
withstand force), while the proteins provide resilience (hence abil-
ity to recover from a force), giving two independent dimensions 
to fracture risk. The evidence presented in this study shows that 
Raman spectroscopy provides information over and above DXA, 
suggesting that it may capture a different dimension of fracture 
risk. The authors hypothesize that the Raman test on nails is 
measuring a surrogate marker of protein quality in the bone.
conclusions
The data presented in the study demonstrate that Raman spec-
troscopy can provide novel insight into a subject’s fracture risk, 
and this information is sufficiently distinct from other readily 
available fracture risk predictors that it can be combined with 
those approaches to deliver a powerful algorithm that outper-
forms the information that can be derived from DXA T-score 
and clinical data alone.
Limitations of the study. The study was a cross-sectional 
study looking at existing recent fracture (in the absence of a 
major trauma) against absence of adult fracture. It is not 
designed to demonstrate the potential for the method to pre-
dict future fracture. It is intended to capture two distinct 
groups of people with different states of bone health, with the 
presence of fragility fracture (the cause of which cannot be 
attributed to a major trauma) taken to confirm the presence of 
poor bone health.
The FRAN study was designed to utilize the occur-
rence vs. nonoccurrence of a fragility fracture as its gold stan-
dard assessment of bone health. This is due to the absence 
of any widely accepted gold standard reference measurement 
technique and the practical and ethical issues that would 
be involved in collecting biopsy samples (which is relatively 
straightforward for fracture cases undergoing corrective 
orthopedic surgery, but challenging for healthy controls). 
However, fracture measurement is an imperfect gold stan-
dard; the clinical end point measured in the FRAN study is 
not a definitive end point from a negative (absence) view point 
but is robust from a positive (presence) view point. Absence 
of a fracture is NOT definitive proof of healthy bone, as the 
subject may have thus far avoided low impact trauma. Due to 
the heterogeneity of the nonfracture control group, the out-
come is expressed in terms of risk of fracture rather than a 
definitive diagnosis.
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